This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

BluePrint molecular subtyping profile for breast cancer. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2014

Breast cancer is the most common cancer affecting women, with > 200,000 newly identified cases every year in the United States. It is estimated that in 2014, 232,670 American women will be diagnosed with breast cancer and 40,000 will die of the disease. If identified while localized, treatment of breast cancer has a 98.5% 5-year survival rate; however, this drops to 84.6% once the cancer has spread to the lymph nodes and drops further to 25.0% if the cancer has metastasized. Adjuvant chemotherapy is used in the treatment of many patients with a high risk of breast cancer recurrence to reduce the risk of recurrence following surgical resection. This has resulted in improvements in both disease-free survival (DFS) and overall survival (OS) of women with breast cancer. Physicians and patients must balance the benefits and risks of adjuvant chemotherapy and antiestrogen therapy, however, because the majority of women who receive these adjuvant treatments will not benefit from them, but will be exposed to the associated toxicities. Common toxicities of breast cancer chemotherapies include nausea and vomiting, myelosuppression, hair loss, mucositis, and cognitive decline. Less common adverse effects include heart failure, thromboembolic events, premature menopause, and leukemia. Given the need to balance the benefits and harms of adjuvant chemotherapy, it is generally offered on the basis of risk factors that have been shown to be associated with greater disease-specific mortality or greater chance of distant recurrence (metastasis), such as patient age, menopause status, disease stage and location, histologic and nuclear tumor grade, hormonal receptor status (estrogen receptor [ER], progesterone receptor [PR], and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2, commonly referred to as HER2]), and measures of proliferation of the tumor. Several guidelines and prognostic models have also been developed to aid physicians and patients in making complex treatment decisions. Three of the most common guidelines are the National Comprehensive Cancer Network (NCCN) guidelines, the St. Gallen guidelines, and the National Institutes of Health (NIH) Consensus Conference Statement (2000) guidelines. One of the reasons that not all cancers respond similarly to treatment with adjuvant chemotherapy is that breast cancer is now being regarded as having 5 subtypes: (1) basal-like; (2) whether the tumor expresses the oncogene ERBB2 (HER2); (3) normal; (4) luminal A; and (5) luminal B. These intrinsic breast cancer subtypes differ according to their cellular origins, etiologies, cancer recurrence, response to chemotherapy, and OS. Consequently, in recent years, a number of molecular tests have been developed with the goal of identifying the intrinsic subtype of patients' tumors, thus indicating who has a higher risk of recurrence and is therefore more likely to benefit from adjuvant chemotherapy. The BluePrint Molecular Subtyping Profile for Breast Cancer (Agendia Inc.) is designed to be used in conjunction with Agendia's prognostic MammaPrint Breast Cancer Recurrence Signature to provide additional information regarding therapy response.

The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=17415

Subject indexing assigned by CRD

Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; Genetic Testing; Genome, Humans; Microarray Analysis; Neoplasm Grading; Prognosis; RNA, Messenger

English

United States

An English language summary is available.

HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

32015000360

16/03/2015